Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family by unknown
POSTER PRESENTATION Open Access
Antibody-dependent cellular cytotoxicity-mediating
antibodies from an HIV-1 vaccine efficacy trial
preferentially use the VH1 gene family
M Bonsignori1*, J Pollara1, MA Moody1, TB Kepler2, X Chen1, TC Gurley1, DM Kozink1, DJ Marshall1, JF Whitesides1,
J Kaewkungwal3, S Nitayaphan4, P Pitisuttithum5, S Rerks-Ngarm6, JH Kim7, NL Michael7, DC Montefiori1, H Liao1,
G Ferrari1, BF Haynes1
From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012
Background
The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine efficacy
trial showed an estimated efficacy of 31%. The immune
correlates analysis raised the hypothesis that the observed
protection in RV144 may be partially due to Antibody-
Dependent Cellular Cytotoxicity (ADCC)-mediating anti-
bodies in the presence of low levels of Env IgA antibodies.
In this study we analyzed the Ig VH family usage of vac-
cine-induced ADCC mAbs isolated from memory B cells
of vaccinees.
Methods
From a total of 321,945 memory B-cells of 6 vaccinees we
obtained 23 mAbs that mediated ADCC using IgG+ mem-
ory B-cell cultures (n=9) and Env-specific flow cytometric
single memory B-cell sorting (n=14). ADCC activity was
measured using both E.CM243 gp120-coated and E.
CM235-infected target cells in a flow-based assay.
Results
ADCC-mediating mAbs displayed a disproportionate
usage of VH1 family genes (17/23; 74%), in particular the
VH1-2 gene segment (10/17; 59%), as recently observed
for CD4bs broadly neutralizing antibodies (HAAD
bNAbs). In contrast, only 17.1% of 111 heavy chains iso-
lated from cultures that did not mediate ADCC used the
VH1 gene. VH1 ADCC-mediating mAbs showed a high
degree of V(D)J amino acid similarity to both the VH
(68-84%) and VL (70-87%) HAAD motifs. V(D)J rearran-
gements displayed modest levels of affinity maturation
(0.5-5.1% for heavy chains and 0.4-4.3% for light chains).
While none of the VH1 ADCC-mediating mAbs was cap-
able of mediating HIV-1 neutralization, the strength of
their ADCC activity correlated with the levels of heavy
chain somatic mutations (p=0.02). We produced the
reverted unmutated ancestor antibodies of two VH1
ADCC-mediating mAbs: one bound to B.MN Env and
both reacted against autoantigens.
Conclusion
ADCC-mediating antibodies induced by the ALVAC-HIV/
AIDSVAX-B/E vaccine underwent limited affinity matura-
tion, and preferentially used VH1 gene segments which
share the HAAD motif with CD4bs bNAbs. These obser-
vations raise the hypothesis that HIV-1 Env preferentially
selects VH1 family usage for distinct subsets of antibodies
with different functions.
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